Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6BON2)

Drug Name

(S)-zacopride Drug Info

Synonyms

CHEMBL28992; Tocris-1795; NCGC00025295-01; AC1O7H1O; SCHEMBL5373467; ZINC3961; GTPL2289; SCHEMBL16233195; PDSP2_001618; PDSP1_001634; BDBM50056419; UNII-9GN3OT4156 component FEROPKNOYKURCJ-CYBMUJFWSA-N; 4-Amino-N-(S)-1-aza-bicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy-benzamide; 4-amino-N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide; 4-amino-N-[(8S)-1-azabicyclo[2.2.2]octan-8-yl]-5-chloro-2-methoxybenzamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 6604914
TTD Drug ID: DM6BON2

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Discontinued Drug(s)

Investigative Drug(s)

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting 5-HT 3B receptor (HTR3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[3]
SEROTONIN	DMOFCRY	Discovery agent	N.A.	Investigative	[4]
2-methyl-5-HT	DM1S5CB	N. A.	N. A.	Investigative	[5]
QUIPAZINE	DMPY6IG	Discovery agent	N.A.	Investigative	[4]
MESULERGINE	DMKGWAH	Discovery agent	N.A.	Investigative	[6]
bilobalide	DM09Z35	Discovery agent	N.A.	Investigative	[7]
2-(4-Methyl-piperazin-1-yl)-quinoline	DMB8OY6	Discovery agent	N.A.	Investigative	[4]
BRL-24682	DMSB4EW	Discovery agent	N.A.	Investigative	[8]
6-(4-Methyl-piperazin-1-yl)-phenanthridine	DM1HAWR	Discovery agent	N.A.	Investigative	[4]
trichloroethanol	DMNALMF	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting 5-HT 3A receptor (HTR3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dolasetron	DMMG26Z	Nausea	MD90	Approved	[10]
Alosetron	DML2A03	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[11]
Tropisetron	DMNSJ7V	Fibromyalgia	MG30.01	Approved	[12]
Palonosetron	DMBHMOX	Nausea	MD90	Approved	[13]
Levetiracetam	DMTGDN8	Epilepsy	8A60-8A68	Approved	[12]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[14]
Cilansetron	DMP0NGX	Irritable bowel syndrome	DD91.0	Phase 3	[15]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[3]
Norcisapride	DMJSKUI	Gastroesophageal reflux disease	DA22.Z	Discontinued in Phase 2	[16]
YM-114	DML2IXO	Nausea	MD90	Discontinued in Phase 2	[17]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 3A receptor (HTR3A)	TTPC4TU	5HT3A_HUMAN	Antagonist	[2]
5-HT 3B receptor (HTR3B)	TTR6K75	5HT3B_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2289).
2	Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
3	Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
4	Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
5	The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature. 1999 Jan 28;397(6717):359-63.
6	Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. J Med Chem. 1997 Oct 24;40(22):3670-8.
7	Ginkgolide B and bilobalide block the pore of the 5-HT eceptor at a location that overlaps the picrotoxin binding site. Neuropharmacology. 2011 Feb-Mar;60(2-3):488-95.
8	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
9	Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity. Brain Res Mol Brain Res. 2005 Dec 14;142(2):146-50.
10	Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
11	Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
12	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
13	Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
14	Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
15	Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
16	mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
17	Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.